Deals this week: STRATA Skin Sciences, Biocept, Cardiva Medical


STRATA Skin Sciences has secured exclusive US distribution rights of Ellipse USA’s family of products, branded as Nordlys.

Manufactured in Denmark, the Nordlys brand includes uniquely designed class of lasers with patented dual-mode filtration.

Pursuant to the agreement, STRATA will distribute Ellipse lasers for three years, extendable up to five years subject to achieving minimum sales target. In exchange, STRATA will pay an annual license fee and a sales commission on each product to Ellipse.

Ellipse designs and develops laser-based dermatologic solutions, while STRATA is a medical technology company focused on the therapeutic and diagnostic dermatology market.

Molecular diagnostics company, Biocept, has announced collaboration with Catalyst Pharmaceuticals, a biopharmaceutical company currently developing Firdapse® (amifampridine phosphate) for the treatment of LEMS (lambert eaton myasthenic syndrome), a rare neuromuscular disorder associated with small cell lung cancer (SCLC).

Under the agreement, Biocept will provide its Target Selector platform, a liquid biopsy test, at free of cost to all the patients enrolled in Catalyst’s ongoing phase III clinical trial designed to demonstrate the safety and efficacy of Firdapse.

The subjects will have long-term access to the test, allowing them to test every six months for up to two years. The test will help detect the early signs of SCLC.

Vascular access management products developer, Cardiva Medical, has raised $30m in equity financing, which will be used to fund the commercial expansion of its bio-absorbable vascular closure system and other advance technologies in its pipeline.

The financing round has seen the participation of new investor, Luther King Capital Management, and existing investors, PTV Healthcare Capital and Canepa Advanced Healthcare Fund.

In a move to develop in-vitro diagnostic (IVD) solutions to evaluate adverse reactions to anti-thyroid drugs, TBG Diagnostics, in association with Medigen Corp, has partnered with the National Taiwan University Hospital (NTUH).

"The subjects will have long-term access to the test, allowing them to test every six months for up to two years."

Pursuant to the agreement, TBG-Medigen partnership will receive exclusive worldwide license to develop and distribute an IVD product that can identify and prevent patients suffering from Grave’s Disease (GD) from further developing life-threatening agranulocytosis after taking Thionamide drugs.

In an agreement to make Utipro Plus, a medical device used to control and prevent uncomplicated urinary tract infections (UTIs), available in five Nordiac countries, the device maker, Noventure, has granted Riksforbundet Sexuell Upplysning (RFSU) rights to distribute the product in Denmark, Finland, Iceland, Norway and Sweden.

RFSU will launch the product in 2018, making it available in 21 European countries.


Image: Ellipse USA’s Nordlys platform. Photo: courtesy of Ellipse A/S.